Amgen Pays $71M In Multistate Drug-Marketing Settlement
Amgen Inc. agreed Tuesday to a $71 million settlement with 48 state attorneys general who accused the drugmaker of marketing its anemia drug Aranesp and plaque psoriasis drug Enbrel, both biologic...To view the full article, register now.
Already a subscriber? Click here to view full article